High-Yielding Synthesis of Antiviral Drug Candidate

High-Yielding Synthesis of Antiviral Drug Candidate

Author: European Journal of Organic Chemistry

The COVID-19 pandemic is caused by the coronavirus SARS-CoV-2. Drugs for the treatment of this disease are urgently needed. The antiviral compound EIDD-2801 (molnupiravir, pictured above) has been identified as a potential drug candidate against COVID-19 and is currently in phase II clinical trials. The existing route for its synthesis, however, gives EIDD-2801 from uridine in a rather low yield of 17 %.

C. Oliver Kappe, Doris Dallinger, University of Graz, Austria, and colleagues have developed an improved synthesis of EIDD-2801 from uridine (pictured below) by strategically reordering the synthetic steps. The reaction sequence starts with the activation of uridine with 1,2,4-triazole and continues with a telescoped acetonide protection/esterification and a telescoped hydroxyamination/acetonide deprotection. Telescoped reaction sequences consist of two or more than one one-pot procedures that are performed back-to-back without a work-up step in-between. A continuous flow process was used for the final acetonide deprotection, which improved selectivity and reproducibility.

 

Compared to the original route, the yield of EIDD-2801 was improved to 61 %. This strategy also requires fewer isolation steps because of the two telescoped procedures (acetonide protection/esterification and hydroxyamination/acetonide deprotection) included within the five‐step route.


 

Also of Interest

News: Coronavirus Drug Molnupiravir

  • 05 October 2021

Molnupiravir significantly reduces risk of hospitalization and/or death, according to Merck

thumbnail image: Coronavirus Drug Molnupiravir

News: Improved Synthesis Route for Molnupiravir

  • 04 August 2021

Efficient synthesis from cheap and easily available cytidine

thumbnail image: Improved Synthesis Route for Molnupiravir

Research Highlight: How Molnupiravir Causes SARS-CoV-2 to Mutate and Die

  • 07 September 2021
  • Author: Roswitha HarrerORCID iD

Mechanism might apply to various viral polymerases and could explain broad-spectrum antiviral activity of molnupiravir

thumbnail image: How Molnupiravir Causes SARS-CoV-2 to Mutate and Die

News: High-Yielding Synthesis of Antiviral Drug Candidate

  • 19 November 2020

Improved preparation of EIDD‐2801, currently in clinical trials for COVID-19 treatment

thumbnail image: High-Yielding Synthesis of Antiviral Drug Candidate

News: Oral Drug Blocks SARS-CoV-2 Transmission in Ferrets

  • 09 December 2020

Repurposed ribonucleoside analogue inhibitor of influenza viruses

thumbnail image: Oral Drug Blocks SARS-CoV-2 Transmission in Ferrets

 

 

 

Leave a Reply

Kindly review our community guidelines before leaving a comment.

Your email address will not be published. Required fields are marked *